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Background: Clinical complications of Sjoegren’s syndrome include myelitis and skin manifestations. There is scarce
observational data and a lack of randomised controlled studies regarding the treatment of Sjoegren’s syndrome in
the presence of such complications.
Case presentation: Here we report the case of a 41-year-old Caucasian female patient with biopsy-proven
Sjoegren’s syndrome who initially presented with generalized exanthema and subsequently developed acute extensive
transverse myelitis. In view of the rapid deterioration we opted for an intensive treatment using a combination of
corticosteroid pulse therapy, plasmapheresis and cyclophosphamide, which we later changed to rituximab. Under
that treatment the skin manifestations resolved entirely whereas transverse myelitis showed incomplete remission.
Conclusion: Severe neurological and dermatological complications may occur in Sjoegren’s syndrome. This
suggests a close yet currently unclear pathogenetic relationship. Intensive immunosuppressant treatment resulted
in significant improvement of both symptom clusters. Skin manifestations may precede other severe complications
in Sjoegren’s syndrome and therefore require particular attention.
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Sjoegren’s syndrome (SS) is an autoimmune disease that
primarily affects the exocrine glands and leads to kerato-
conjunctivitis and xerostomia [1]. Systemic manifestations
may also occur including myoarthralgia, vasculitis and
dermatological findings such as dry skin, urticaria or cu-
taneous vasculitis [1-5]. SS affects the nervous system in
approximately 20% of cases and rarely causes severe
complications like acute transverse myelitis [6].
The co-existence of SS and psoriasis has rarely been
described before, the mutual immunological factors being
unclear [7]. The management of SS with neurological or
dermatological complications is still a matter of debate.
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unless otherwise stated.particularly intensive treatment [1-3,5,8]. In such cases
cyclophosphamide appears to be most effective for
achieving symptom remission [1-3,5]. In addition, limited
experience suggests that patients with extraglandular
manifestations of SS benefit from long-term treatment
with rituximab [8,9].
Here we report the case of a 41-year-old female patient
with biopsy-proven SS who rapidly developed severe exan-
thema and extensive transverse myelitis.Case presentation
A 41-year-old Caucasian woman was admitted to the de-
partment of dermatology with generalized maculopapular
exanthema (Figure 1). Within three days she developed fa-
tigue, headache, incomplete third cranial nerve palsy, urin-
ary retention, paraparesis (strength 1-2/5 bilaterally) and
sensory loss below level T4. Subsequently, tetraparesis
(strength arms 3/5, legs 1/5) and dyspnoea with reduced. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Macroscopic dermatological findings: maculopustular and squamous exanthema of the entire integument. (A) Left leg (B)
cheek and forehead (C) chin.
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been suspected since the patient had suffered from xero-
phthalmia, xerostomia and myoarthralgias since the late
1990’s and SS-A-antibodies had been tested positive. The
patient had temporarily been treated with oral corticoste-
roids for sicca symptoms two years before admission.
Diagnostic findings
Magnetic resonance (MR) imaging revealed extensive
transverse myelitis reaching from the caudal medulla
oblongata to level C7 (Figure 2A and B) as the cause of
tetraparesis. Cerebrospinal fluid (CSF) showed mild lym-
phomonocytic pleocytosis and impairment of the brain-
blood-barrier. CSF culture was negative as were all poly-
merase chain reaction studies of the CSF for fungal and
viral infection. Furthermore cytology of CSF was nega-
tive for malignancy. Identical oligoclonal bands in serum
and CSF indicated systemic inflammation. Testing for
human immunodeficiency virus (HIV) was negative. Anti-
nuclear antibodies were elevated (1: 960) but all other
tests for autoimmune antibodies were negative includ-
ing aquaporin 4. The previous finding of positive SS-A
antibodies was not replicated in our laboratory. This
discrepancy is unusual but can be explained by different
test sensitivities. The diagnosis of SS was confirmed accord-
ing to consensus criteria by labial salivary gland biopsy,
positive Schirmer’s test and salivatory gland scintigraphy[10]. Erythematous macules and papulosquamous lesions
characterized the clinical appearance of the skin lesions.
For further examination, a skin biopsy was performed and
showed psoriasiform dermatitis with aggregated neurophilic
granulocytes in parakeratotic foci (Figure 3, insets B and C)
and exocytosis of neutrophils presenting as an intraepithe-
lial pustule (Figure 3, inset A).Differential diagnosis
Concerning the neurological differential diagnosis, there
was no history of previous radiation to the spine or clinic-
ally apparent optic neuritis, aquaporin 4 antibodies were
negative and there were no brain abnormalities suggestive
of MS on magnetic resonance imaging (MRI). Further-
more, we could neither find evidence for an arterial occlu-
sion, a compressive aetiology or a viral or fungal infection
nor another connective tissue disease -especially leuko-
cytoclastic vasculitis or lupus erythematosus. Subacute
cutaneous lupus erythematosus (SCLE) as an important
differential diagnosis of psoriasiform dermatitis was ex-
cluded since histological characteristics for SCLE (lique-
factive degeneration of the basal layer, edema of the
upper dermis, scattered interface, perivascular and peri-
adnexal lymphocytic infiltrates) were absent. In synopsis
of all clinical and serological findings we considered the
extensive transverse myelitis to be SS-associated.
Figure 2 Sagittal T2-weighted (A) and T1-weighted, gadolinium enhanced (B) MRI pictures: Confluent contrast-enhanced lesions in the
cervical spinal cord extending to the caudal medulla oblongata (A and B, white arrows); no evidence of myelitis after cyclophosphamide
therapy (C and D).
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Due to the rapid worsening of the patient’s condition
and the evidence of severe demyelination on MRI we initi-
ated seven sessions of plasmapheresis and simultaneouscorticosteroid pulse therapy (1 gr/d for 5 days followed by
oral tapering). With this treatment regimen tetraparesis
and dyspnoea gradually improved but generalized ex-
anthema worsened. For long-term therapy we chose
Figure 3 Histological findings (hematoxylin-eosin staining; overview 40x, inset 200x; Punch biopsy from left upper arm): neutrophils
and lymphocytes forming intraepithelial pustules (inset A, red arrow), aggregated neutrophilic granulocytes in parakeratotic foci
(inset B, red arrow), orthokeratosis associated with parakeratosis and mild superficial perivascular lymphocytic infiltrates around
dilated vessels (insert C, red arrow).
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imum cumulated dose of cyclophosphamide after
6 months we switched to rituximab (375 mg/m2 every
six months). Since then, the patient is regularly seen
for the administration of rituximab and has had no relapse
so far. The combination of plasmapheresis, corticosteroid
pulse therapy and subsequent immunosuppression signifi-
cantly improved the severe symptoms, but only an incom-
plete remission was achieved: while moderate paraparesis
with decreased sensation of both legs and urinary retention
remained (strength 3/5 bilaterally), generalized maculo-
papulosquamous exanthema, dyspnea and oculomotor
impairment resolved completely. A follow-up MRI after
cyclophosphamide therapy showed significant improve-
ment and no evidence of myelitis (Figure 2C and D).
Conclusion
We report a patient with biopsy-proven SS who pre-
sented with an acute rash, acute transverse myelopathyand coincident cranial neuropathy. It is likely that the
psoriasiform dermatitis represents a skin manifestation
of SS. Hence, fulminant skin manifestations in SS may
herald severe organ involvement and therefore require
particular attention. Cutaneous manifestations of SS
described to far are dry skin, immunological inflamma-
tory conditions such as vasculitis and hypergammaglo-
bulinaemic purpura. In rare cases, SS is associated with
neutrophilic, granulomatous disorders. The pathogen-
etic relationship between neurological and dermato-
logical manifestations remains elusive and needs further
investigation. In particular, the role of circulating Th17
cells, which are known to play a major role in both
Sjoegren’s syndrome and psoriasis needs to be clarified
[11-13]. Following this, anti-interleukin-17 (anti-IL17)
treatment could be an option for therapy. Of note re-
cent findings demonstrate a T cell epitope mimicry be-
tween Sjögren’s syndrome Antigen A (SSA)/Ro60 and
skin bacteria [14].
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optimal treatment of SS cases with central nervous sys-
tem (CNS) involvement remains unclear. In our case,
high dose corticosteroids, plasmapheresis and long-term
immunosuppression with cyclophosphamide followed by
rituximab was obviously effective in stopping the sus-
pected autoimmune inflammation but could not reverse
the neurological damage. Therefore, in any case of un-
clear myelopathy, the coincidence of skin manifestations
and cranial neuropathies should serve as a red-flag for
an autoimmune disorder and should result in further
screening for autoimmune disorders including SS.
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